Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours

@article{Essen2007ReportOS,
  title={Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours},
  author={Martijn van Essen and Eric P. Krenning and Boen L. R. Kam and Wouter W de Herder and Maarten O. van Aken and Dik J. Kwekkeboom},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2007},
  volume={35},
  pages={743 - 748}
}
Treatment with the radiolabelled somatostatin analogue 177Lu-octreotate results in tumour remission in 47% of patients with gastroenteropancreatic neuroendocrine tumours. Adding capecitabine to 177Lu-octreotate, as a radio-sensitiser, may enhance these anti-tumour effects. We now present the short-term toxicity profile of this novel combination. Seven patients were treated with 7.4 GBq 177Lu-octreotate and capecitabine (1650 mg/m2 per day) for 2 weeks with an intended number of four cycles… CONTINUE READING
38 Citations
14 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 14 references

High - dose In - 111 octreotide therapy in combination with radiosensitizing 5 - FU chemotherapy for treatment of SSR - expressing neuroendocrine tumors . [ Abstract ]

  • G Kong, E Lau, S Ramdave, RJ Hicks
  • J Nucl Med
  • 2005

High-dose In-111 octreotide therapy in combination with radiosensitizing 5-FU chemotherapy for treatment of SSR-expressing neuroendocrine tumors

  • G Kong, E Lau, S Ramdave, RJ. Hicks
  • [Abstract] J Nucl Med 2005;46(Suppl 2):151P
  • 2005
1 Excerpt

Treatment with the radiolabeled somatostatin analogue [ 177 Lu - DOTA 0 , Tyr 3 ] octreotate in patients with gastro - entero - pancreatic ( GEP ) tumors

  • DJ Kwekkeboom, JJ Teunissen, WH Bakker, PP Kooij, WW deHerder, RA Feelders
  • J Clin Oncol
  • 2005

Treatment with the radiolabeled somatostatin analogue [177Lu-DOTA,Tyr3]octreotate in patients with gastro-entero-pancreatic (GEP) tumors

  • DJ Kwekkeboom, JJ Teunissen, WH Bakker, PP Kooij, WW de Herder, RA Feelders
  • J Clin Oncol
  • 2005
1 Excerpt

Phase I study of peptide receptor radionuclide therapy with [ 111 In - DTPA 0 ] Octreotide : the Rotterdam experience

  • R Valkema, M deJong, WH Bakker, WA Breeman, PP Kooij, PJ Lugtenburg
  • Semin Nucl Med
  • 2002

Similar Papers

Loading similar papers…